AVI BioPharma (AVII)
Symbol Info
Listed Symbol AVII
Name AVI BioPharma
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2018-12-31
Latest Fiscal Revenue $-
Latest Fiscal EPS $
Price Info
21 Day Moving Average $-
21 Day EMA $-
50 Day Moving Average $-
50 Day EMA $-
200 Day EMA $-
200 Day Moving Average -
52 Week High $
52 Week Low $-
52 Week Change $
Alpha
Beta
Standard Deviation
R2
Periods
Share Information
10 Day Average Volume -
20 Day Average Volume -
30 Day Average Volume -
50 Day Average Volume -
Outstanding Shares -
Float Shares -
Percent Float -
Short Interest -
Short Percent Float -
Short Interest Ratio -
Short Date
Holders
Institutions 117
Institute Holdings Date 2012-05-31
Institute Bought Previous 3 Months 6,959,608
Institute Holdings Percent 27.800000
Institute Sold Previous 3 Months 2,550,052
Insider Holdings Date 2012-03-31
Insider Bought Previous 3 Months 30,000
Insider Holdings Percent 9.20%
Insider Sold Previous 3 Months -
Insiders Shares Owned -
Price Change
7 Day Price Change $-
7 Day Percent Change -
21 Day Price Change $-
21 Day Percent Change -
30 Day Price Change $-
30 Day Percent Change -
Month To Date Price Change $-
Month To Date Percent -
90 Day Price Change $-
90 Day Percent Change -
Quarter To Date $-
Quarter To Date Percent -
180 Day Price Change $-
180 Day Percent Change -
200 Day Price Change $-
200 Day Percent Change -
Year To Date $-
Year To Date Percent -
Profile
Description Sarepta Therapeutics is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of Sarepta's product candidates are at an early stage of development.
Details
Issue Type CS
Market Cap $-
Sec Type
Auditor KPMG LLP
Total Shares Outstanding -
CEO Douglas S. Ingram
Employees 499
Last Audit UQ
Classification
CIK 0000873303
Industry Biotechnology
Sector Healthcare
NAICS Pharmaceutical Preparation Manufacturing(325412)
Info
Address 215 First Street
Suite 415
Cambridge, MA 2142
Website http://www.sarepta.com
Facisimile
Telephone +1 617 274-4000
Email investors@sarepta.com
Key Ratios
Profitability
EBIT Margin -156.4
EBITDA Margin -150.2
Pre-Tax Profit Margin -4,806.8
Profit Margin Cont -
Gross Margin 85.50
Profit Margin TOT -
Income Statements
Revenue $-
Revenue Per Share $-
Revenue 3 Years $398.10
Revenue 5 Years $136.18
Valuation Measures
PE Ratio -
Enterprise Value $-
Price To Sales -
Price To Free Cash -
PE High Last 5 Years -
Price To Book 6.1
Price To Cash Flow -
PE Low Last 5 Years -
Price To Tangible Book -
Financial Strength
Total Debt To Equity 0.4
Int Coverage -16.5
Current Ratio 8.8
Leverage Ratio 1.6
Quick Ratio 7.4
Long Term Debt To Capital 0.30
Assets
Receivables Turnover 2.8
Invoice Turnover 0.20
Assets Turnover 0.10
Management Effectiveness
Return Assets -38.09
Return On Equity -63.43
Return On Capital -40.24
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type


Your Recent History
NASDAQ
AVII
Avi Biopha..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.